Why the study?
Does hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin improve survival and what is its toxicity in patients with nonresectable HCC, and how do HBV/HCV infections affect these outcomes?
Population
31 patients with nonresectable hepatocellular cancer confined to the liver
Design
Cohort
Follow-up
median survival 15 months
Authors
Loading...
Positive hepatitis serology was associated with shorter survival after hepatic arterial infusion in unresectable HCC; leaves open whether antiviral therapy modifies outcomes.
Does hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin improve survival and what is its toxicity in patients with nonresectable HCC, and how do HBV/HCV infections affect these outcomes?
Hepatic arterial infusion of FLAP induces partial responses in nonresectable HCC, but positive hepatitis serology significantly increases myelotoxicity and is associated with shorter survival.
Patt et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: